PMS-IRBESARTAN 75mg Pharmascascience Treatment Treatment of Definitely Hypertension, Type 2 (100 Tablets)

Dosage form Box of 100 capsules
Specifications Irbesartan

Ingredient

Composition information	Content
Irbesartan	75mg

Uses

Indications

HC - PMS Irbesartan 75mg Pharmascism 100V is indicated in the following cases:

Treatment Hypertension is idiopathic. The active inhibitor of Angiotensin LL through AT1 receptor intermediaries, regardless of the origin or synthetic sugar of Angiotensin l. Selective antagonism of Angiotensin II receptors (AT1) increases plasma renin levels and angiotensin-II concentration, and reduces plasma aldosteron levels. Serum potassium concentration is not affected by the successor by Irbesartan in the recommended dose.

Irbesartan does not inhibit the enzyme (kininase-lL), an enzyme that produces angiotensin II and can also decompose Bradykinin to the inactive metabolites. Activities of Irbesartan do not need metabolic activities.

Pharmacokinetics

absorption

Theravings absorb fast through the gastrointestinal tract with bioavailability of 60-80%. Food does not change many of the drugs of the drug. The peak concentration of plasma is about 1-2 hours after a dose of oral.

Distribution

LRBESartan binds 96% to plasma proteins. The distribution of the drug is about 63-93 liters. The concentration of medication in the blood reaches a stable equilibrium after 3 days of taking the drug.

Metabolism

partially metabolic drugs in the liver to form non -active products.

Elimination

Eliminating drugs through bile and urine. After oral or intravenously, about 20% of the drug excreted through the urine in the form of metabolism and less than 2% in non -metabolic form. The sale time is 11-15 hours. Irbesartan is not eliminated by hemorrhage.

Before taking PMS-IRBESARTAN 75mg Pharmascascience Treatment Treatment of Definitely Hypertension, Type 2 (100 Tablets)

How to use

drink with a sufficient amount of water. Can be used with food or not.

Dosage

Starting dose and maintenance dose are usually usually 150 mg x 1 time/day. Irbesartan at a dose of 150 mg x 1 time/day to control blood pressure for 24 hours better at a dose of 75 mg, however, the starting dose of 75 mg can be considered, especially in patients with dialysis and in people older than 75 years old.

In patients with uncontrolled dose 150 mg once a day, Irbesartan can be increased to 300 mg, or may use other lowering drugs. In particular, adding diuretics such as hydrochlorothiazide has shown to increase the effects of Irbesartan.

In patients with type 2 diabetes with hypertension, the beginning of 150 mg of Irbesartan x once a day, then adjusts up to 300 mg x 1 time/day as the maintenance dose in the treatment of kidney disease.

Renal failure: No dose adjustment for patients with renal function. Lower starting dose (75 mg) can be considered for patients with dialysis.

Hepatic failure: No dose adjustment for medium and mild liver failure. There is no clinical research for patients with severe liver failure.

Older patients: Although the beginning of treatment should be considered with 75 mg in patients over 75 years old, often do not need to adjust the dose for older patients.

Pediatric: Irbesartan is not recommended for children and young people because they do not have enough data on effect and safety.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.

What to do when overdose?

No specialized treatment for overdose with Irbesartan. Patients should be closely monitored, symptomatic treatment and supportive treatment. The proposed measures include vomiting and/or gastric lavage. Activated carbon can be helpful in treating overdose. Irbesartan is not eliminated by hemorrhage.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using HC - PMS Irbesartan 75mg Pharmascascience, you may experience unwanted effects (ADR).

Very common, ADR> 1/10

metabolic: hyperkalemia.

Common, ADR> 1/100

Urinary tract: increased creatine kinase plasma.

Body: dizziness , posture dizziness, nausea, vomiting, musculoskeletal pain, Hematuria posture, fatigue.

Uncommon, 1/1000

Body: tachycardia, chest pain, cough, diarrhea , indigestion, heartburn, rash, sexual dysfunction.

Not determined frequency

Body: headache , tinnitus, taste rebellion.

kidney: renal function. blood: leukemia vasculitis.

bone - joints: joint pain, muscle pain (in some cases there is an increase in plasma creatine levels), cramps.

Metabolism: hyperkalemia.

skin: angioedema, rash, urticaria .

Hepatitis: Hepatitis, Liver function often.

Instructions on how to handle ADR

When experiencing side effects of the drug, it is necessary to stop using and notify the doctor or go to the nearest medical facility for timely treatment.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

HC - PMS Irbesartan 75mg Pharmascasciction 100V Contraindicated in the following cases:

Sensitive to the active ingredient or any ingredient of the drug.

Pregnant women.

Caution when using

Reducing internal volume: Hypotension symptoms, especially after the first dose, can occur in patients with decreased volume and/or sodium reduction due to strong diuretic, strict salt abstain, diarrhea or vomiting. These conditions should be adjusted before using Irbesartan.

Hypertension caused by renal artery: Increased risk of severe hypotension and renal failure in patients with kidney stenosis on both sides or artery stenosis on a functional kidney treated with drugs acting on the Renin - Angiotensin - Aldosterone system. While not recorded with Irbesartan, the same use should be anticipated with Angiotensin II receptor antagonists.

Kidney failure and kidney transplantation: When using Irbesartan in patients with renal function, periodic monitoring of potassium and serum creates are recommended. There is no study on the use of Irbesartan in new kidney transplant patients.

Patients with type 2 diabetes with hypertension and renal disease: The effect of Irbesartan on both kidney and cardiovascular events is the same in subgroups, in an analysis performed in research with progressive patients with renal disease. In particular, appear more disadvantage in women and other non -white people.

Hyperbysical hyperka: as well as drugs that affect the Renin - Angiotensin - Aldosterone system, hyperkalemia may occur during treatment with Irbesartan, especially when kidney failure, clear protein due to kidney disease in diabetes patients, and/or heart failure, poetry close to potassium blood in patients with risk.

Lithium: The combination of lithium and Irbersartan is not recommended.

Aortic stenosis and mitral stenosis, obstructive hypertrophy of myocardial disease: like other vasodilators, especially cautious when prescribed patients with aortic stenosis, or mitral valve stenosis or obstructive hypertrophy.

primary Aldosteron: Patients with primary Aldosteron intense in general, not responding to antihypertensive drugs operating through inhibition of the renin - angiotensin - aldosteron system. Therefore, the use of Irbesartan is not recommended.

General: In patients with vascular tone and renal function depend mainly on the activities of the renin-angiotensin-aldosteron system (such as patients with severe congestive heart failure, potential renal disease, including kidney artery stenosis), treatment with conversion inhibitors or Angiotensin II antagonists have an impact on this system that causes acute hypotension, hyperemia, rarely acute, minimum, rare or acute. As with any other antihypertensive drugs, excessive hypotension in patients with ischemia or cardiovascular disease due to ischemia can lead to myocardial infarction or stroke.

Pediatric patients: Lrbesartan has been studied on children from 6 years old to 16 years old but the current data is not enough to support the expansion of children's treatment until there are more data.

The ability to drive and operate machinery

There are no studies conducted on the effects on the ability to control the train and operate machinery. Based on the pharmacological properties, Irbesartan doesn't seem to affect this ability. When controlling the train and operating machinery, it should be noted that dizziness or fatigue may appear during treatment.

Pregnancy

Contraindicated drugs for pregnant women. In the first 3 months of pregnancy contraindicated due to caution. In the 3 months or the last 3 months of pregnancy: may directly affect the renin-analiotensin system, causing kidney failure in the fetus or infant deformed face, even causing fetal death. When detecting pregnancy, stopping the drug as soon as possible, if the drug has been used for a long time, it is necessary to check the skull and kidney function by ultrasound for the fetus.

The period of breastfeeding

There is no information on the use of Irbesartan during breastfeeding, Irbesartan is not recommended and prioritizes replacement therapies that are better for use for use during breastfeeding have been established, especially while caring for infants and premature babies.

Interactive drug

with other anti -hypertension drugs: Other anti -hypertension may increase the hypotension effect of Irbesartan. However, Irbesartan can still be combined with other anti -hypertension drugs such as beta blockers, calcium blockers or thiazid diuretics. An advance treatment with high doses can create a decrease in blood volume and the risk of hypotension when taking Irbesartan.

Potassium supplements or potassium diuretic: simultaneous use of Irbesartan with diuretics that hold potassium or potassium supplements can be done. Increased blood potassium concentration.

Lithium: Increased serum and recovery lithium concentration has been reported when combined with enzyme inhibitors, closely monitor serum lithium concentration.

Irbesartan is metabolized mainly by CYP 2C9 and may be by both combined with glucuronic acid. The effect of CYP 2C9 induction drugs such as rifampicin for pharmacokinetics of Irbesartan has not been evaluated. Experimental data does not allow predicting interactions between specialized drugs related to the isenzyme of Cytochrome P480 such as CYP 1A1, CYP 1A2, CYP 2A8, CYP 2B8, CYP 2D6, CYP 2E1 or CYP 3A4. It is less likely to inhibit with glucuronic acid that leads to meaningful clinical interactions.

In vitro: The interactions between Irbesartan and warfarin , tolbutamid or Nifedipin have been observed. However, there is no pharmacokinetic and pharmacokinetic interaction recorded when used in combination with Irbesartan with Warfarin for healthy people.

Storage

Store in a dry place at temperatures below 30 ° C.

To be out of reach of children.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.